• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

α2-巨球蛋白将纤溶酶原激活限制在RC2A白血病细胞表面。

Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.

作者信息

Stephens R W, Tapiovaara H, Reisberg T, Bizik J, Vaheri A

机构信息

Department of Virology, University of Helsinki, Finland.

出版信息

Cell Regul. 1991 Dec;2(12):1057-65. doi: 10.1091/mbc.2.12.1057.

DOI:10.1091/mbc.2.12.1057
PMID:1724917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC361905/
Abstract

Human RC2A myelomonocytic leukemia cells are able to activate the prourokinase (pro-u-PA) they secrete so that active u-PA is present both in serum-free conditioned medium from these cells, as well as on the cell surface. When the cells are grown in serum-containing medium, no u-PA activity can be found in the medium but active u-PA is found bound to the cell surface where it can generate bound plasmin. This distribution of u-PA activity was shown to be, first, the net result of slow inactivation of free active u-PA by serum inhibitor(s) and simultaneous rapid uptake of u-PA onto the cell surface. Binding to cells was at least six times faster than inactivation by 10% serum. The principal serum inhibitor of u-PA was identified as alpha 2-macroglobulin (alpha 2M), and prior inactivation of u-PA by purified human alpha 2M was also shown to prevent uptake of u-PA activity onto cells. Second, although endogenous u-PA could form covalent complexes with purified alpha 2M in the culture medium of RC2A cells, covalent alpha 2M complexes were not formed by u-PA on the cell surface; the u-PA taken up in this compartment was protected against alpha 2M inhibition. u-PA anchored to plastic surfaces via monoclonal antibodies to the amino-terminal region of u-PA was also protected against alpha 2M, suggesting that the protection of cell surface u-PA results from a steric effect. These results provide evidence as to how the active u-PA produced by leukemia cells can contribute to proteolytic activity on their cell surface in the presence of serum inhibitors.

摘要

人RC2A骨髓单核细胞白血病细胞能够激活它们所分泌的纤溶酶原激活剂(pro-u-PA),使得活性u-PA既存在于这些细胞的无血清条件培养基中,也存在于细胞表面。当细胞在含血清的培养基中生长时,培养基中未发现u-PA活性,但在细胞表面发现有活性u-PA,它能产生结合型纤溶酶。u-PA活性的这种分布首先被证明是血清抑制剂使游离活性u-PA缓慢失活以及u-PA同时快速摄取到细胞表面的净结果。与细胞的结合比10%血清导致的失活至少快6倍。u-PA的主要血清抑制剂被鉴定为α2-巨球蛋白(α2M),并且还表明纯化的人α2M预先使u-PA失活可防止u-PA活性摄取到细胞上。其次,尽管内源性u-PA可在RC2A细胞的培养基中与纯化的α2M形成共价复合物,但细胞表面的u-PA不会形成共价α2M复合物;在这个区室摄取的u-PA受到保护而免受α2M抑制。通过针对u-PA氨基末端区域的单克隆抗体锚定在塑料表面的u-PA也受到α2M的保护,这表明细胞表面u-PA的保护是由空间效应导致的。这些结果提供了证据,说明白血病细胞产生的活性u-PA在存在血清抑制剂的情况下如何有助于其细胞表面的蛋白水解活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9822/361905/f7edcbd997d4/cellregul00037-0098-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9822/361905/34f624028316/cellregul00037-0097-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9822/361905/f7edcbd997d4/cellregul00037-0098-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9822/361905/34f624028316/cellregul00037-0097-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9822/361905/f7edcbd997d4/cellregul00037-0098-a.jpg

相似文献

1
Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.α2-巨球蛋白将纤溶酶原激活限制在RC2A白血病细胞表面。
Cell Regul. 1991 Dec;2(12):1057-65. doi: 10.1091/mbc.2.12.1057.
2
Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.在α2-巨球蛋白分泌存在的情况下,组织型纤溶酶原激活物(t-PA)对人黑色素瘤细胞表面纤溶酶原的激活作用。
Cell Regul. 1990 Nov;1(12):895-905. doi: 10.1091/mbc.1.12.895.
3
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.人肉瘤细胞上尿激酶原和纤溶酶原的激活:一个具有表面结合反应物的蛋白水解系统。
J Cell Biol. 1989 May;108(5):1987-95. doi: 10.1083/jcb.108.5.1987.
4
Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.人横纹肌肉瘤细胞表面的纤溶酶原激活物原激活:重组2类纤溶酶原激活物抑制剂对新形成的尿激酶型纤溶酶原激活物的定位和失活作用
Proc Natl Acad Sci U S A. 1990 Mar;87(6):2230-4. doi: 10.1073/pnas.87.6.2230.
5
Persistence of plasmin-mediated pro-urokinase activation on the surface of human monocytoid leukemia cells in vitro.
Int J Cancer. 1993 Feb 1;53(3):499-505. doi: 10.1002/ijc.2910530324.
6
Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.12-O-十四烷酰佛波醇-13-乙酸酯诱导的K562白血病细胞培养物中蛋白水解活性的下调:1型纤溶酶原激活物抑制剂过量导致活性尿激酶耗竭
J Cell Physiol. 1989 Jul;140(1):119-30. doi: 10.1002/jcp.1041400115.
7
Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor.无血清原代大鼠肝细胞培养物中尿激酶的存在及其在激活肝细胞生长因子中的作用。
Cancer Res. 1996 Jun 15;56(12):2837-43.
8
Structural and functional characterization of the inhibition of urokinase by alpha 2-macroglobulin.
Biochemistry. 1985 Jul 16;24(15):3902-7. doi: 10.1021/bi00336a014.
9
Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages.培养的人单核细胞-巨噬细胞分泌的尿激酶型纤溶酶原激活剂及其抑制剂。
J Cell Physiol. 1985 Jan;122(1):125-32. doi: 10.1002/jcp.1041220119.
10
Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.内源性产生的尿激酶的功能抑制降低了人黑色素瘤细胞系中的细胞增殖。
Proc Natl Acad Sci U S A. 1989 Jul;86(14):5424-8. doi: 10.1073/pnas.86.14.5424.

引用本文的文献

1
Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases.神经系统疾病患者脑脊液中组织型纤溶酶原激活物的活性
J Clin Pathol. 1996 Jul;49(7):577-80. doi: 10.1136/jcp.49.7.577.

本文引用的文献

1
Cell lines derived from a human myelomonocytic leukaemia.
Br J Haematol. 1982 Aug;51(4):595-604. doi: 10.1111/j.1365-2141.1982.tb02823.x.
2
The inhibition of high and low molecular weight urokinase in plasma.
Blood. 1980 Mar;55(3):430-6.
3
Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators.
Eur J Biochem. 1983 Nov 15;136(3):517-22. doi: 10.1111/j.1432-1033.1983.tb07771.x.
4
Novel properties of human monocyte plasminogen activator.人单核细胞纤溶酶原激活剂的新特性
Eur J Biochem. 1984 Mar 1;139(2):253-8. doi: 10.1111/j.1432-1033.1984.tb08001.x.
5
Complex-formation and inhibition of urokinase by blood plasma proteins.血浆蛋白对尿激酶的复合物形成及抑制作用。
Biochem J. 1983 Oct 1;215(1):123-31. doi: 10.1042/bj2150123.
6
Minactivin expression in human monocyte and macrophage populations.人单核细胞和巨噬细胞群体中的米那激肽释放酶表达。
Blood. 1985 Aug;66(2):333-7.
7
Binding and activation of plasminogen on the platelet surface.纤溶酶原在血小板表面的结合与激活。
J Biol Chem. 1985 Apr 10;260(7):4303-11.
8
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.人纤溶酶原激活剂尿激酶55,000道尔顿形式的细胞结合位点。
J Cell Biol. 1985 Jan;100(1):86-92. doi: 10.1083/jcb.100.1.86.
9
Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors.白血病细胞产生活性尿激酶:与实体瘤细胞系的新区别。
Leuk Res. 1988;12(5):419-22. doi: 10.1016/0145-2126(88)90061-6.
10
Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.纤溶酶原激活物抑制剂1型和2型对组织型和尿激酶型纤溶酶原激活物的抑制动力学
Eur J Biochem. 1988 Jul 15;175(1):33-9. doi: 10.1111/j.1432-1033.1988.tb14162.x.